Key Points
- Director Jean Jacques Bienaime bought 1,000 shares on March 11 at an average price of $21.55, raising his direct stake to 38,415 shares (a 2.67% increase) and disclosed via an SEC Form 4 filing.
- Immunome shares fell about 3.0% to $20.37, with a market cap near $2.30 billion; the company reported a negative EPS of ($0.75) for the quarter, missing estimates and showing steep negative margins.
- Analysts are generally positive—10 Buy vs. 1 Sell—giving a consensus "Moderate Buy" and an average target price of $33.45, though individual ratings and targets vary.
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) Director Jean Jacques Bienaime bought 1,000 shares of Immunome stock in a transaction dated Wednesday, March 11th. The stock was acquired at an average price of $21.55 per share, with a total value of $21,550.00. Following the acquisition, the director directly owned 38,415 shares of the company's stock, valued at approximately $827,843.25. This represents a 2.67% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Immunome Stock Down 3.0%
Shares of Immunome stock traded down $0.62 during midday trading on Friday, hitting $20.37. The company's stock had a trading volume of 658,445 shares, compared to its average volume of 1,529,619. Immunome, Inc. has a 1-year low of $5.15 and a 1-year high of $27.65. The firm has a market capitalization of $2.30 billion, a P/E ratio of -8.40 and a beta of 2.12. The stock has a 50-day simple moving average of $22.74 and a 200-day simple moving average of $17.99.
Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%. As a group, sell-side analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current year.
Institutional Investors Weigh In On Immunome
Hedge funds and other institutional investors have recently made changes to their positions in the business. Assetmark Inc. acquired a new stake in Immunome in the 3rd quarter valued at approximately $39,000. BNP Paribas Financial Markets increased its position in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock worth $60,000 after acquiring an additional 2,909 shares during the period. Strs Ohio acquired a new position in Immunome during the 4th quarter valued at $64,000. Tower Research Capital LLC TRC grew its position in Immunome by 121.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock worth $65,000 after purchasing an additional 3,802 shares during the last quarter. Finally, BIT Capital GmbH acquired a new position in shares of Immunome during the third quarter valued at about $69,000. 44.58% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on IMNM. Lake Street Capital lifted their target price on shares of Immunome from $22.00 to $32.00 and gave the company a "buy" rating in a research note on Tuesday, December 16th. Guggenheim lifted their price objective on Immunome from $25.00 to $35.00 and gave the company a "buy" rating in a research report on Tuesday, December 16th. Wedbush reaffirmed an "outperform" rating and issued a $31.00 target price on shares of Immunome in a research report on Thursday, January 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunome in a report on Thursday, January 22nd. Finally, Stephens lowered their price target on Immunome from $33.00 to $30.00 and set an "overweight" rating for the company in a research note on Wednesday, March 4th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $33.45.
View Our Latest Stock Analysis on Immunome
Immunome Company Profile
(
Get Free Report)
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
